Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QRX003 in Netherton Syndrome
NCT06953466Phase 3Recruiting
- Sponsor
- Quoin Pharmaceuticals Ltd.
- Start
- Oct 2025
- Primary completion
- Dec 2026
- Modality
- Transdermal Patches, Hydrogel Systems, Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of QRX003 in Netherton syndrome (NS), sponsored by Quoin Pharmaceuticals Ltd.. Started Oct 2025; status: recruiting.
02
Drugs
QRX003
03
Conditions
Netherton syndrome (NS)
Beyond the preview
Go deeper on NCT06953466.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06953466.